CHANGING THE PARADIGM
OF MEDICINE

Developing a novel class of complete microbiota ecosystem products and
microbiome therapies to address unmet challenges in human diseases.

Our preclinical stage programs and related information are disclosed below:

Program Indication Product Type(s) Discovery Preclinical Clinical
MVT-201 Infectious Diseases Complete Microbiota HPM®    
MVT-601 Skin disorder Bacterial consortia & HPM®    
MVT-2401 Oncology Bacterial consortia & HPM®  
MVT-701 Healthy ageing Bacterial consortia    
MVT-1001 Sports performance Bacterial consortia    

Program: MVT-201

Indication:Infectious Diseases

Product Type(s): Complete Microbiota HPM®

Preclinical Fase

Program: MVT-601

Indication: Skin disorder

Product Type(s): Bacterial consortia & HPM®

Preclinical Fase

Program: MVT-2401

Indication:Oncology

Product Type(s): Bacterial consortia & HPM®

Discovery fase

Program: MVT-701

Indication: Healthy ageing

Product type(s): Bacterial consortia

Preclinical fase

Program: MVT-1001

Indication:Sports performance

Product type(s): Bacterial consortia

Preclinical fase

Over the last years we have built our platform powered by innovation leading to tangible products and services already marketed.

We are currently focused on developing novel biotherapeutics based on complete microbiota ecosystem products that are at preclinical stage for various medical applications. Additionally, we have a large and diverse bacterial strain collection for the development of novel LBPs and probiotics to cover the patients’ needs.

MICROVIABLE THERAPEUTICS

CONTACT US